TransCode Therapeutics, Inc. (RNAZ) has a negative trailing P/E of -0.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -393.55%.
Criteria proven by this page:
Overall SharesGrow Score: 47/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -1,160.3 | 0.00 | -1,043.97 | 0.00 | - |
| 2019 | -28,882.2 | 297.91 | -15,979.44 | 0.00 | - |
| 2020 | -9,318.1 | -30.25 | -6,408.18 | 0.00 | - |
| 2021 | -2,022.7 | -16.77 | 678.39 | 0.00 | - |
| 2022 | -321.6 | -0.03 | 1,743.07 | 0.00 | - |
| 2023 | -1.2 | 0.01 | 14.10 | 0.00 | - |
| 2024 | -1.4 | 0.01 | -11.66 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-2,359.09 | $0.00 | $-453.44K | - |
| 2019 | $-72.00 | $0.00 | $-764.14K | - |
| 2020 | $-293.76 | $0.00 | $-2.74M | - |
| 2021 | $-648.00 | $0.00 | $-6.94M | - |
| 2022 | $-1,080.00 | $0.00 | $-35.13M | - |
| 2023 | $-3,453.53 | $0.00 | $-18.55M | - |
| 2024 | $-47.14 | $0.00 | $-16.75M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-8.96 | $-8.96 – $-8.96 | $500K | $500K – $500K | 1 |
| 2027 | $-6.72 | $-6.72 – $-6.72 | $9.7M | $9.7M – $9.7M | 1 |
| 2028 | $-5.60 | $-5.60 – $-5.60 | $9.9M | $9.9M – $9.9M | 1 |
| 2029 | $-5.04 | $-5.04 – $-5.04 | $27.8M | $27.8M – $27.8M | 1 |
